Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Profound Medical Corp (NASDAQ: PROF) closed at $4.3 down -0.92% from its previous closing price of $4.34. In other words, the price has decreased by -$0.92 from its previous closing price. On the day, 1.44 million shares were traded. PROF stock price reached its highest trading level at $4.52 during the session, while it also had its lowest trading level at $4.24.
Ratios:
For a deeper understanding of Profound Medical Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.07 and its Current Ratio is at 8.53. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Lake Street on July 23, 2024, initiated with a Buy rating and assigned the stock a target price of $16.50.
On July 16, 2024, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $9 to $12. On November 28, 2023, Stifel started tracking the stock assigning a Hold rating and target price of $11.Stifel initiated its Hold rating on November 28, 2023, with a $11 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 16 ’25 when Menawat Arun Swarup bought 12,027 shares for $4.73 per share. The transaction valued at 56,888 led to the insider holds 587,089 shares of the business.
Menawat Arun Swarup bought 10,003 shares of PROF for $43,263 on May 15 ’25. The CEO now owns 575,062 shares after completing the transaction at $4.33 per share. On Nov 12 ’24, another insider, Goodman Abbey, who serves as the Officer of the company, bought 13,014 shares for $8.11 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PROF now has a Market Capitalization of 129722664 and an Enterprise Value of 98846512. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.91 while its Price-to-Book (P/B) ratio in mrq is 3.29. Its current Enterprise Value per Revenue stands at 8.349 whereas that against EBITDA is -2.378.
Stock Price History:
The Beta on a monthly basis for PROF is 0.64, which has changed by -0.42666668 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, PROF has reached a high of $9.17, while it has fallen to a 52-week low of $3.76. The 50-Day Moving Average of the stock is -13.27%, while the 200-Day Moving Average is calculated to be -27.53%.
Shares Statistics:
For the past three months, PROF has traded an average of 80.37K shares per day and 210820 over the past ten days. A total of 30.05M shares are outstanding, with a floating share count of 26.82M. Insiders hold about 10.74% of the company’s shares, while institutions hold 42.08% stake in the company. Shares short for PROF as of 1756425600 were 689661 with a Short Ratio of 8.58, compared to 1753920000 on 640783. Therefore, it implies a Short% of Shares Outstanding of 689661 and a Short% of Float of 2.77.
Earnings Estimates
A detailed examination of Profound Medical Corp (PROF) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.37, with high estimates of -$0.28 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.48 and -$1.74 for the fiscal current year, implying an average EPS of -$1.57. EPS for the following year is -$1.31, with 5.0 analysts recommending between -$0.91 and -$1.51.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $6.56M this quarter.It ranges from a high estimate of $7.01M to a low estimate of $5.66M. As of the current estimate, Profound Medical Corp’s year-ago sales were $3.93MFor the next quarter, 5 analysts are estimating revenue of $10.43M. There is a high estimate of $12.15M for the next quarter, whereas the lowest estimate is $7.86M.
A total of 5 analysts have provided revenue estimates for PROF’s current fiscal year. The highest revenue estimate was $25.11M, while the lowest revenue estimate was $21.54M, resulting in an average revenue estimate of $23.72M. In the same quarter a year ago, actual revenue was $15.22MBased on 5 analysts’ estimates, the company’s revenue will be $50.27M in the next fiscal year. The high estimate is $65.29M and the low estimate is $43.61M.
